Advertisement

Female Pattern Hair Loss

  • Elise A. Olsen

Abstract

• Decrease in hair density in the central (vertex, mid and frontal) scalp, bitemporal and parietal regions in women.

• Miniaturization of affected hairs.

• Two ages of onset: early (post-puberty to third decade) and late (age 40+ years).

• Signs of hyperandrogenism (hirsutism, irregular periods) or hyperandrogenemia occur in a subset of women with female pattern hair loss (FPHL) but most women with FPHL have neither.

• Many, but not all, affected women respond to antiandrogens or 5α-reductase inhibitors with increased hair growth indicating an androgen etiology in at least some cases of FPHL.

Keywords

Hair Loss Hair Growth Cyproterone Acetate Androgenetic Alopecia Terminal Hair 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Agarwal SK, Hughes CL, Hirsutism In Olsen EA (Ed) (2004) Disorders of Hair Growth: Diagnose and Treatment. McGraw-Hill, NYGoogle Scholar
  2. 2.
    Aram H (1979) Treatment of female androgenetic alopecia with cimetidine. Gastroenterology; 76: 504-508Google Scholar
  3. 3.
    Assiz R, Sanchez A, Knochenhauer ES, et al (2004) Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab; 89: 453–462CrossRefGoogle Scholar
  4. 4.
    Avram MR, Cole JP, Gandelman M, et al (2002) The potential role of minoxidil in the hair transplanting setting. J Dermatol Surg; 28: 10: 894-900CrossRefGoogle Scholar
  5. 5.
    Barman JM, Pecoraro V, Astore I (1969) Biological basis of the inception and evolution of baldness. J Gerontol; 24: 163-168PubMedGoogle Scholar
  6. 6.
    Beek CH (1950) A study on extension and distribution of the human body-hair. Dermatologica; 101: 317-331PubMedCrossRefGoogle Scholar
  7. 7.
    Bingham KD, Shaw DA (1973) The metabolism of testosterone by human male scalp hair. J Endocrinol; 57; 811-819CrossRefGoogle Scholar
  8. 8.
    Birch MP, Messenger JF, Messenger AG (2001) Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol; 144: 297-304 PubMedCrossRefGoogle Scholar
  9. 9.
    Birch MP, Lashen H, Agarwal S et al (2006) Female pattern hair loss, sebum excretion and the end-organ response to androgens. Br J Dermatol; 154: 85-89PubMedCrossRefGoogle Scholar
  10. 10.
    Burke BM, Cunliffe WJ (1985) Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia [Letter]. Br J Dermatol; 112: 124-125PubMedCrossRefGoogle Scholar
  11. 11.
    Camacho F (2001) Hissutismo: enfoque dclinico terapeutico. Act Terap Dermatol; 24: 190-206Google Scholar
  12. 12.
    Cameron DR, Braunstein GD (2004) Androgen replacement therapy in women. Fertil Steril; 82: 273-289PubMedCrossRefGoogle Scholar
  13. 13.
    Carey AH, Waterworth D, Patel K, et al (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet; 3: 1873-1876PubMedCrossRefGoogle Scholar
  14. 14.
    Carmina E, Lobo RA (2003) Treatment of hyperandrogenic alopecia in women. Fertil Steril; 79: 91-95PubMedCrossRefGoogle Scholar
  15. 15.
    Cela E, Robertson C, Rush K, et al (2003) Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol; 149: 439-442 PubMedCrossRefGoogle Scholar
  16. 16.
    Chen WC, Thiboutot D, Zouboulis CC (2002) Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol; 119: 992-1007PubMedCrossRefGoogle Scholar
  17. 17.
    Choi MH, Yoo YS, Chung BC (2001) Biochemical roles of testosterone and epitestosterone to 5α-reducatase as indicators of male-pattern baldness. J Invest Dermatol; 116: 57-61PubMedCrossRefGoogle Scholar
  18. 18.
    Conrad F, Paus R (2004) Östrogene und der Haarfollikel. JDDG; 2: 412-423PubMedCrossRefGoogle Scholar
  19. 19.
    Conrad F, Ohnemus U, Bodo E, et al (2004) Estrogens and human scalp hair growth – still more questions than answers. J Invest Dermatol; 122: 840-842PubMedCrossRefGoogle Scholar
  20. 20.
    Corvol P, Michaud A, Menard J, et al (1975) Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology; 97: 52-58PubMedCrossRefGoogle Scholar
  21. 21.
    Courtois M, Loussouvn G, Hourseau C, et al (1995) Ageing and hair cycles. Br J Dermatol; 132: 86-93PubMedCrossRefGoogle Scholar
  22. 22.
    Cusan L, Dupont A, Gomez JL, et al (1990) Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol; 23: 462-469PubMedCrossRefGoogle Scholar
  23. 23.
    Cusan L, Dupont A, Gomez JL, et al (1994) Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril; 61: 281-287PubMedGoogle Scholar
  24. 24.
    Dawber RPR, Sonnex T, Ralfs I. (1982) Oral anti-androgen treatment of common baldness in women. Br J Dermatol; 107 (suppl 22):20Google Scholar
  25. 25.
    Deloche C, de Lacharrière O, Misciali C, et al (2004) Histological features of peripilar signs associated with androgenetic alopecia. Arch Dermatol Res; 295(10): 422-428PubMedCrossRefGoogle Scholar
  26. 26.
    DeVillez RL, Jacobs JP, Szpunar CA, et al (1994) Androgenetic alopecia in the female: treatment with 2% topical minoxidil solution. Arch Dermatol; 30: 303-307CrossRefGoogle Scholar
  27. 27.
    Drake LD, Hordinsky M, Fiedler V, et al (1999) The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol; 41: 550-554PubMedGoogle Scholar
  28. 28.
    Ekoe JM, Burkhardt P, Ruedi B (1980) Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica; 160: 398-404PubMedCrossRefGoogle Scholar
  29. 29.
    Ferry JJ, Turner SW, Albert DG, et al (1996) Hemodynamic effects of minoxidil following intravenous infusion in untreated hypertensive patients. Clin Pharmacol Ther; 59: 166CrossRefGoogle Scholar
  30. 30.
    Fischer TW, Burmeister G, Schmidt HW et al (2004) Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol; 150: 341-345PubMedCrossRefGoogle Scholar
  31. 31.
    Futterweit W, Dunaif A, Yeh H-C, et al (1988) The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol; 19: 831-836PubMedCrossRefGoogle Scholar
  32. 32.
    Gan DCC, Sinclair RD (2005) Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc; 10: 184-189PubMedCrossRefGoogle Scholar
  33. 33.
    Gassmueller J, Hoffmann R, Webster A (2007) A treatment of androgenetic alopecia using topical fulvestrant solution in males and post-meonopausal females. Poster presentation at European Hair Research Society meeting, London, Great Britain, June 2007Google Scholar
  34. 34.
    Gomez JL, Dupont A, Cusan L, et al (1992) Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med; 92: 465-470PubMedCrossRefGoogle Scholar
  35. 35.
    Goss PE, Ingle JN, Martino S, et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med; 349: 1793-802PubMedCrossRefGoogle Scholar
  36. 36.
    Guerrera M, Ciulla MP (1986) A quantitative evaluation of hair loss: the phototrichogram. J Appl Cosmetol; 4: 61-66Google Scholar
  37. 37.
    Guerrera M, Rebora A (1996) Anagen hairs may fail to replace telogen hairs in early androgenic female alopecia. Dermatology; 192: 28-31CrossRefGoogle Scholar
  38. 38.
    Hamilton JB (1942) Male hormone stimulation is prerequisite to an incite in common baldness. Am J Anat; 71: 451-452CrossRefGoogle Scholar
  39. 39.
    Hamilton JB (1951) Patterned loss of hair in man: types and incidence. Ann NY Acad Sci; 53: 708-728PubMedCrossRefGoogle Scholar
  40. 40.
    Hammerstein J, Meckies J, Leo-Rossberg I, et al (1975) Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism or virilism. J Steroid Biochem; 6: 827-836PubMedCrossRefGoogle Scholar
  41. 41.
    Hoffmann R, Rot A, Niiyama S, et al (2001) Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. J Invest Dermatol; 117(6): 1342-1348PubMedCrossRefGoogle Scholar
  42. 42.
    Iorizzo M, Vincenzi C, Voudouris S, et al (2006) Finasteride treatment of female pattern hair loss. Arch Dermatol; 142: 298-302PubMedCrossRefGoogle Scholar
  43. 43.
    Jackson D, Church RE, Ebling FJ (1972) Hair diameter in female baldness. Br J Dermatol; 87: 361-367PubMedCrossRefGoogle Scholar
  44. 44.
    Jacobs JP, Szpunar CA, Warner ML (1993) Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol; 32: 758-762PubMedCrossRefGoogle Scholar
  45. 45.
    Kaufman KD, Olsen EA, Whiting D, et al (1998) Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol; 39:578-589PubMedCrossRefGoogle Scholar
  46. 46.
    Kossard S (1994) Postmenopausal frontal fibrosing alopecia. Arch Dermatol; 130: 770-774PubMedCrossRefGoogle Scholar
  47. 47.
    Labrie F, Luu-The V, Labrie C, et al (2000) Intracrinology and the skin. Hormone Res 2000; 54: 213-229CrossRefGoogle Scholar
  48. 48.
    Lobo RA, Shoupe D, Serafini P, et al (1985) The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril; 43: 200-205PubMedGoogle Scholar
  49. 49.
    Lucky AW, Piacquadio DJ, Ditre CM, et al (2004) A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol; 50: 541-553PubMedCrossRefGoogle Scholar
  50. 50.
    Ludwig E (1964) Die androgenetische alopecie bei der Frau. Arch Klin Exp Dermatol; 219: 558PubMedCrossRefGoogle Scholar
  51. 51.
    Ludwig E (1977) Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol; 97: 247-254PubMedCrossRefGoogle Scholar
  52. 52.
    Maguire HC Jr, Kligman AM (1963) Common baldness in women. Geriatrics; 18: 329-334 Google Scholar
  53. 53.
    Mansouri P, Mortazavi M, Eslami M et al (2005) Androgenetic alopecia and coronary artery disease in women. Dermatol Online J; 11(3): 2PubMedGoogle Scholar
  54. 54.
    Messenger AG, Rundegren J (2004) Minoxidil: mechanisms of action on hair growth. Br J Dermatol; 150: 186-194PubMedCrossRefGoogle Scholar
  55. 55.
    Mortimer CH, Rushton H, James KC (1984) Effective medical treatment for common baldness in women. Clin Exp Dermatol; 9: 342-350PubMedCrossRefGoogle Scholar
  56. 56.
    Niiyama S, Happle R, Hoffmann R (2001) Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol; 11: 195-198PubMedGoogle Scholar
  57. 57.
    Norwood OT (2001) Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg; 27: 53-54PubMedCrossRefGoogle Scholar
  58. 58.
    Oh H-S, Smart RC (1996) An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad Sci; 93: 12525-12530PubMedCrossRefGoogle Scholar
  59. 59.
    Olsen EA (1994) Androgenetic alopecia. In: Olsen EA (Ed) (1994) Disorders of Hair Growth: Diagnosis and Treatment. New York: McGraw-Hill; p. 257-283Google Scholar
  60. 60.
    Olsen EA (1994) Clinical tools for assessing hair loss. In Olsen EA (Ed) (1994) Disorders of Hair Growth: Diagnosis and Treatment. New York: McGraw-Hill; p. 59-69Google Scholar
  61. 61.
    Olsen EA (1999) The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol; 40: 106-109PubMedCrossRefGoogle Scholar
  62. 62.
    Olsen EA (2001) Female pattern hair loss. J Am Acad Dermatol; 45: S70-S80PubMedCrossRefGoogle Scholar
  63. 63.
    Olsen EA (2003) Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol; 48: 253-262PubMedCrossRefGoogle Scholar
  64. 64.
    Olsen EA (2004) Pattern hair loss in men and women, in Olsen EA (Ed) Hair Disorders: Diagnosis and Treatment. McGraw-Hill, NYGoogle Scholar
  65. 65.
    Olsen EA (2005) Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc; 10(3): 217-221PubMedCrossRefGoogle Scholar
  66. 66.
    Olsen EA, Weiner MS (1987) Topical minoxidil in male pattern baldness: effect of discontinuation of treatment . J Am Acad Dermatol; 17: 97-101PubMedCrossRefGoogle Scholar
  67. 67.
    Olsen EA, Weiner MS, DeLong ER, et al (1985) Topical minoxidil in early male pattern baldness. J Am Acad Dermatol; 13: 185-192PubMedCrossRefGoogle Scholar
  68. 68.
    Olsen EA, Bergfeld W, Cotsarelis G, et al (2003) Summary of NAHRS-sponsored workshop on cicatricial alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol; 48:103-110PubMedCrossRefGoogle Scholar
  69. 69.
    Olsen EA, Messenger AG, Shapiro J, et al (2005) Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol; 52: 301-311PubMedCrossRefGoogle Scholar
  70. 70.
    Olsen EA, Hordinsky M, Whiting D, et al (2006) The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol; 55: 1014-1023PubMedCrossRefGoogle Scholar
  71. 71.
    Olsen EA, Whiting D, Bergfeld W, et al (2007) A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam vs placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol; 57(5): 767-774 PubMedCrossRefGoogle Scholar
  72. 72.
    Olszewska M, Rudnicka L (2005) Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol; 4: 637-640PubMedGoogle Scholar
  73. 73.
    Orfanos CE, Vogels L (1980) Lokaltherapie der Alopecia Androgenetica mit 17a –Östradiol. Dermatologica; 161: 124-132PubMedCrossRefGoogle Scholar
  74. 74.
    Orme S, Cullen DR, Messenger AG (1999) Diffuse female hair loss: are androgens necessary? Br J Dermatol; 141: 521-523PubMedCrossRefGoogle Scholar
  75. 75.
    Park JH, Yoon JB, Sim WY, et al (2001) The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol; 145: 95-99CrossRefGoogle Scholar
  76. 76.
    Peereboom-Wynia JD, van der Willigen AH, van Joost T, et al (1989) The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Dermatol Venereol; 69: 395-398Google Scholar
  77. 77.
    Price VH, Roberts JL, Hordinsky M, et al (2000) Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol; 43 (5 Pt 1): 768-76PubMedCrossRefGoogle Scholar
  78. 78.
    Puerto AM, Mallol J (1990) Regional scalp differences of the androgenetic metabolic pattern in subjects affected by male pattern baldness. Rev Esp Fisiol; 46: 289-286PubMedGoogle Scholar
  79. 79.
    Riggs BL, Hartmann LC (2003) Seletive estrogen-receptor modulators – mechanism of action and application to clinical practice. N Engl J Med; 348: 618-629PubMedCrossRefGoogle Scholar
  80. 80.
    Roberts JL, Fielder V, Imperato-McGinley J, et al (1999) Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol; 41:555-563PubMedGoogle Scholar
  81. 81.
    Rushton DH, Ramsay ID (1992) The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol; 36: 421-424 CrossRefGoogle Scholar
  82. 82.
    Rushton DH, Futterweit W, Kingsley DH, et al (1991) Quantitative assessment of spironolactone treatment of women with diffuse androgen-dependent alopecia. J Soc Cosmet Chem; 42: 317-325Google Scholar
  83. 83.
    Sawaya ME, Price VH (1997) Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol; 109: 296-300PubMedCrossRefGoogle Scholar
  84. 84.
    Schmidt HB, Lindmaier A, Trenz A, et al (1991) Hormone studies in females with androgenic hairloss. Gynecol Obstet Invest; 31: 235-239PubMedCrossRefGoogle Scholar
  85. 85.
    Schweikert HU, Wilson JD (1974) Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab 38: 811-819PubMedCrossRefGoogle Scholar
  86. 86.
    Sciarra F, Toscano V, Concolino G, et al (1990) Anti-androgens: clinical applications. J Steroid Biochem Mol Biol; 37: 349-362PubMedCrossRefGoogle Scholar
  87. 87.
    Shum KW, Cullen DR, Messenger AG (2002) Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol; 47: 733-739PubMedCrossRefGoogle Scholar
  88. 88.
    Sinclair R (2004) The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol; 51: 189-199PubMedCrossRefGoogle Scholar
  89. 89.
    Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol; 152: 466-473PubMedCrossRefGoogle Scholar
  90. 90.
    Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med; 348: 2431-2442PubMedCrossRefGoogle Scholar
  91. 91.
    Smith MA, Wells RS (1964) Male-type alopecia, alopecia areata and normal hair in women: family histories. Arch Dermatol; 89: 95-98PubMedCrossRefGoogle Scholar
  92. 92.
    Thai K-E, Sinclair RD (2002) Finasteride for female androgenetic alopecia. Br J Dermatol; 147: 808-840CrossRefGoogle Scholar
  93. 93.
    Thornton MJ (2002) The biological actions of estrogens on skin. Exp Dermatol; 11: 487-502PubMedCrossRefGoogle Scholar
  94. 94.
    Tindll DJ, Chang CH, Lobl TJ, et al (1984) Androgen antagonists in androgen target tissues. Pharmacol Ther; 24: 367-400 CrossRefGoogle Scholar
  95. 95.
    Tremblay RR (1986) Treatment of hirsutism with spironolactone. Clin Endocrinol Metab; 15: 363-371PubMedCrossRefGoogle Scholar
  96. 96.
    Trost LB, Bergfeld WF, Calgeras E (2006) The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol; 54: 824-844PubMedCrossRefGoogle Scholar
  97. 97.
    Trueb RM (2004) Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology; 209: 202-207PubMedCrossRefGoogle Scholar
  98. 98.
    Ueki R, Tsuboi R, Inaba Y, et al (2003) Phototrichogram analysis of Japanese female subjects with chronic diffuse hair loss. J Investig Dermatol Symp Proc; 8: 116-120PubMedCrossRefGoogle Scholar
  99. 99.
    Unger WP, Hair transplantation in females. In: Unger WP (ed) (1988) Hair Transplantation. Dekker, New York, pp. 295-300Google Scholar
  100. 100.
    Unger WP, Unger RH (2003) Hair transplanting: an important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol; 49: 853-860PubMedCrossRefGoogle Scholar
  101. 101.
    Uno H, Cappas A, Schlagel C (1985) Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques. Am J Dermatopathol; 7: 283-297PubMedCrossRefGoogle Scholar
  102. 102.
    Valsecchi R, Leghissa P, Riva M (2004) Female androgenetic alopecia treated by finasteride: a case forward. Acta Derm Venereol; 84: 488-489PubMedCrossRefGoogle Scholar
  103. 103.
    Vanwayjen RG, Van den Ende A (1995) Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes; 103: 241-251CrossRefGoogle Scholar
  104. 104.
    Venning VA, Dawber RPR (1988) Patterned androgenic alopecia in women. J Am Acad Dermatol; 18: 1073-1077PubMedCrossRefGoogle Scholar
  105. 105.
    Vexiau P, Chaspoux C, Boudou P, et al (2002) Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol; 146: 992-999PubMedCrossRefGoogle Scholar
  106. 106.
    Vierhapper H, Nowotny P, Maier H, et al (2001) Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab; 86: 5752-5764CrossRefGoogle Scholar
  107. 107.
    Vierhapper H, Maier H, Nowotny P, et al (2003) Production rates of testosterone and dihydrotestosterone in female pattern hair loss. Metabolism; 52: 927-929PubMedCrossRefGoogle Scholar
  108. 108.
    Whiting DA (1993) The diagnostic and predictive value of horizontal sections of scalp biopsies in male pattern androgenetic alopecia. J Am Acad Dermatol; 28: 755-763PubMedCrossRefGoogle Scholar
  109. 109.
    Whiting DA (1996) Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol; 35: 899-906PubMedCrossRefGoogle Scholar
  110. 110.
    Whiting DA (1998) Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatol Ther; 8: 24-33Google Scholar
  111. 111.
    Whiting DA, Waldstreicher J, Sanchez M, et al (1999) Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies. Results of finasteride 1 mg treatment of men and postmenopausal women. J Invest Dermatol Symp Proc; 4: 282-284CrossRefGoogle Scholar
  112. 112.
    Yasmin (2007) Physician’s Desk reference; 61: 796-803Google Scholar
  113. 113.
    Zajac JD (2003) Women, androgens and skin (abstract). Exp Dermatol; 12: 224CrossRefGoogle Scholar
  114. 114.
    Zinkernagel MS, Trueb RN (2002) Fibrosing alopecia in a pattern distribution: patterned lichen planopilaris or androgenetic alopecia with a lichenoid tissue reaction pattern? Arch Dermatol; 135: 205-211Google Scholar

Copyright information

© Springer London 2008

Authors and Affiliations

  • Elise A. Olsen
    • 1
  1. 1.Division Dermatology and OncologyDuke University Medical CenterDurhamUSA

Personalised recommendations